News Sentiment

VOR sentiment intelligence

Vor Biopharma Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 48 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 19.14 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

81/100 classification confidence.

Company focus 40

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend active

-7.0% over one week, +33.3% over four weeks, trend active, and below fair value.

Latest direct headline Neutral

Vor Biopharma (VOR) Stock Forum and Discussion

Market Reaction

Price moving ahead of tone

62/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 81/100 classification
One-week reaction -7.0% Price reacting lower
Trend fit Trend active 33.3% over four weeks
Fair value -28.2% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 9
Neutral 35
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 40
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
Stock Titan 10
TradingView 7
TradingKey 5
Seeking Alpha 3
simplywall.st 3
Moomoo 2
Simply Wall Street 2

Event Lens

What the news is about

Classified themes
Market update 27
Earnings 13
Balance sheet 3
Deals and strategy 2
Analyst action 2
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 48
Timothy Sykes Direct company coverage

Vor Biopharma Inc. (VOR) Stock Price | Live Quotes & Charts | NASDAQ

This page provides live quotes and charts for Vor Biopharma Inc. (VOR) stock, showing its current price of $19.14, a decrease of $0.61 (-3.09%). It also indicates that there are no analyst ratings or earnings information currently available for the company. The page is hosted by

Tone
Negative 42/100
Event
Earnings
Published
10 Jul 2026 23:41
Source
Timothy Sykes
Investing.com Canada Direct company coverage

Form 4 Vor Biopharma Inc For: 9 July By Investing.com

This article reports on a Form 4 filing for Vor Biopharma Inc. dated July 9th. It notes that Vor Biopharma Inc. stock (VOR) experienced a -2.76% change. The content also briefly touches upon various financial market data and news headlines.

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 20:16
Source
Investing.com Canada
Stock Titan Direct company coverage

Vor Biopharma (VOR) director receives 42,658 stock options at $20.10 strike

Vor Biopharma director David Zaccardelli has been granted 42,658 stock options with an exercise price of $20.10 per share, expiring on July 6, 2036. These options will vest in 36 equal monthly installments starting August 7, 2026, contingent upon his continued service to the comp

Tone
Neutral 50/100
Event
Market update
Published
09 Jul 2026 20:16
Source
Stock Titan
Stock Titan Direct company coverage

Vor Biopharma (VOR) director submits initial Form 3 with no trades

Vor Biopharma Inc. director David Zaccardelli has filed an initial ownership report on Form 3, indicating no reportable stock or derivative positions and no transactions. This filing serves as a baseline regulatory disclosure, establishing his initial status as a reporting person

Tone
Neutral 50/100
Event
Regulatory and legal
Published
09 Jul 2026 20:16
Source
Stock Titan
Stock Titan Direct company coverage

Vor Bio adds Verona Pharma veteran David Zaccardelli to board

Vor Bio (Nasdaq: VOR) has appointed David Zaccardelli, Pharm.D., to its Board of Directors, bringing over two decades of biopharmaceutical leadership experience. Zaccardelli previously guided Verona Pharma through FDA approval and a $10 billion acquisition by Merck, and Dova Phar

Tone
Positive 76/100
Event
Deals and strategy
Published
07 Jul 2026 20:11
Source
Stock Titan
Stock Titan Direct company coverage

David Zaccardelli joins Vor Biopharma (NASDAQ: VOR) board after Levin exit

Vor Biopharma Inc. announced a change to its board of directors, with Andrew Levin, M.D., Ph.D., resigning effective July 6, 2026. David Zaccardelli, Pharm.D. was appointed as an independent Class II director to fill the vacancy, with his term extending until the 2029 annual meet

Tone
Positive 64/100
Event
Market update
Published
07 Jul 2026 20:11
Source
Stock Titan
Market source Direct company coverage

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Vor Bio announced that on July 1, 2026, its Compensation Committee granted stock options for 71,200 shares and restricted stock units (RSUs) for 15,150 shares to 7 new employees. These grants serve as material inducements for employment, in compliance with Nasdaq Listing Rule 563

Tone
Positive 60/100
Event
Market update
Published
06 Jul 2026 11:41
Source
Market source
Simply Wall Street Direct company coverage

Why Vor Biopharma (VOR) Is Up 27.9% After Broad Russell Index Inclusion And What's Next

Vor Biopharma (VOR) recently experienced a 27.9% stock increase following its inclusion in several Russell indexes, including the Russell 2000 and 3000. While this inclusion boosts visibility and liquidity, the company's investment narrative still hinges on clinical progress, reg

Tone
Negative 40/100
Event
Balance sheet
Published
05 Jul 2026 20:39
Source
Simply Wall Street
Simply Wall Street Direct company coverage

3 Reasons Vor Biopharma (VOR) Looks Pricey On Russell Index Inclusion

Vor Biopharma (VOR) has been added to several Russell indexes, leading to increased trading interest and a significant short-term price jump. However, the company faces skepticism due to negative shareholders' equity, a high Price-to-Book ratio compared to peers, and continued lo

Tone
Negative 38/100
Event
Market update
Published
01 Jul 2026 20:12
Source
Simply Wall Street
www.marketscreener.com Direct company coverage

Vor Biopharma Inc.(NasdaqGS: VOR) added to Russell 3000E Growth Benchmark

Vor Biopharma Inc. (NasdaqGS: VOR), a clinical-stage biotechnology company specializing in autoimmune disease treatments, has been added to the Russell 3000E Growth Benchmark. The company is actively advancing its lead drug, telitacicept, a dual-target fusion protein, through Pha

Tone
Positive 76/100
Event
Market update
Published
29 Jun 2026 08:41
Source
www.marketscreener.com
TradingView Direct company coverage

Enterprise value to EBITDA forward of Vor Biopharma Inc. – NASDAQ:VOR

This article provides financial data for Vor Biopharma Inc. (NASDAQ: VOR), specifically its enterprise value to EBITDA forward. It indicates the market status as closed with no trades and highlights that the data is provided by ICE Data Services and FactSet.

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 18:39
Source
TradingView
TradingView Direct company coverage

Enterprise value to EBIT forward of Vor Biopharma Inc. – NASDAQ:VOR

The article focuses on the enterprise value to EBIT forward for Vor Biopharma Inc. (NASDAQ: VOR). It appears to be a financial data point or analysis provided by TradingView, a platform offering market data and tools for financial analysis. The content primarily lists various fun

Tone
Neutral 50/100
Event
Market update
Published
28 Jun 2026 02:10
Source
TradingView
TradingView Direct company coverage

Vor Biopharma, Inc. Actuals & Estimates (NASDAQ:VOR)

This article provides an overview of Vor Biopharma Inc. (NASDAQ:VOR) stock, including its current price, historical performance, analyst forecasts, and financial data. It highlights that VOR stock has recently increased but shown a yearly decrease, and discusses past earnings and

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 23:39
Source
TradingView
TradingView Direct company coverage

VOR Forecast — Price Target — Prediction for 2027

This article provides a forecast for Vor Biopharma Inc. (VOR) stock, including analyst price targets, historical performance, and financial data. Analysts have provided 1-year max and min estimates for the stock's price, and the article also details its past price movements, vola

Tone
Neutral 50/100
Event
Analyst action
Published
25 Jun 2026 17:09
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Vor Biopharma Inc. – NASDAQ:VOR

This article focuses on the enterprise value to revenue forward metric for Vor Biopharma Inc. (NASDAQ: VOR). It appears to be a financial data point provided by TradingView, a financial platform offering various market tools and data. The content primarily lists the company and t

Tone
Neutral 50/100
Event
Earnings
Published
25 Jun 2026 08:41
Source
TradingView
TradingKey Direct company coverage

Vor Biopharma Inc (VOR) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides a summary of Vor Biopharma Inc's (VOR) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and lists a stock split event for September 17, 2025, which is specified as a 20-to-1 merger. The

Tone
Neutral 50/100
Event
Deals and strategy
Published
18 Jun 2026 19:10
Source
TradingKey
TradingKey Direct company coverage

Vor Biopharma Inc (VOR) Financial Health: Profitability & Balance Sheet Analysis

The article provides a financial health analysis of Vor Biopharma Inc (VOR) from TradingKey. It displays current stock price information, market capitalization, and indicates that key financial data points such as cash and cash equivalents, total assets, total liabilities, free c

Tone
Neutral 50/100
Event
Balance sheet
Published
17 Jun 2026 09:11
Source
TradingKey
TradingKey Direct company coverage

Vor Biopharma Inc (VOR) Institutional Confidence

This article from TradingKey provides an overview of institutional confidence in Vor Biopharma Inc (VOR), including its stock performance and key institutional shareholders. It lists major shareholders such as Forbion Capital Partners, Frazier Life Sciences Management, and Fideli

Tone
Positive 65/100
Event
Market update
Published
17 Jun 2026 08:39
Source
TradingKey
TradingKey Direct company coverage

Vor Biopharma Inc (VOR) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Vor Biopharma Inc (VOR), highlighting analyst ratings, target prices, and EPS expectations. Based on 9 analysts, the stock has a "Buy" rating with a target price of USD 37.875, suggesting a 163.75% upside. The report also notes the w

Tone
Positive 70/100
Event
Earnings
Published
17 Jun 2026 08:11
Source
TradingKey